Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 9/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21618206 | 0.97 | AOC1 (0.45) | AOC1AOC3LOXL2GAACYP2A6 | |
| SCHEMBL23674578 | 0.86 | CYP2E1 (0.43) | AOC1AOC3LOXL2CYP2A6CYP2E1 | |
| SCHEMBL30100775 | 0.86 | CYP2E1 (0.43) | AOC1AOC3LOXL2CYP2A6CYP2E1 | |
| SCHEMBL18149193 | 0.86 | CYP2E1 (0.43) | AOC1AOC3LOXL2CYP2A6CYP2E1 | |
| SCHEMBL11940513 | 0.81 | TNF (0.36) | AOC1AOC3LOXL2CYP2A6CYP2E1 | |
| SCHEMBL11940514 | 0.81 | TNF (0.36) | AOC1AOC3LOXL2CYP2A6CYP2E1 | |
| SCHEMBL12833330 | 0.80 | — | — | |
| SCHEMBL4353616 | 0.80 | — | — | |
| SCHEMBL4351182 | 0.80 | — | — | |
| SCHEMBL1178593 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-117660989-A | Polyion liquid metal hybridization material catalyst and preparation method and application thereof | 北京理工大学 | 2024-03-08 | — | — | CN | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-115772195-A | Pyridine-based phosphine ligand compound and application thereof | 惠州凯特立斯科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-0304962-B1 | NOVEL DIPHOSPHONATES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-08-19 | — | — | EP | disclosed |
| US-5137880-A | Treatment for osteoporosis, pagents disease arthritis | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-5104863-A | Certain bicycloalkane and azabicycloalkane-1,1-diphosphonic acid derivatives useful for treating diseases associated with abnormal calcium and phosphate metabolism | THE PROCTER & GAMBLE COMPANY (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0273514-B1 | NOVEL BICYCLIC DIPHOSPHONATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4939131-A | Certain cycloalkane-1,1-diphosphonic acids and derivatives thereof having the ability to treat diseases associated with abnormal calcium and phosphate metabolism | THE PROCTER & GAMBLE COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| US-4868164-A | OSTEOPOROSIS, ARTHRITIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0304962-A2 | Novel diphosphonates and use thereof in pharmaceutical compositions | THE PROCTER & GAMBLE COMPANY (US) | 1989-03-01 | — | — | EP | disclosed |
| EP-0304961-A2 | Novel diphosphonates and use thereof in pharmaceutical compositions | THE PROCTER & GAMBLE COMPANY (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4687768-A | OSTEOPOROSIS, ARTHRITIS | THE PROCTER & GAMBLE COMPANY (US) | 1987-08-18 | — | — | US | disclosed |
| EP-0189662-A1 | Novel diphosphonates and use thereof in pharmaceutical compositions | THE PROCTER & GAMBLE COMPANY (US) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | AOC1 847/4885AOC3 1619/4885LOXL2 1760/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | AOC1 1589/4885AOC3 954/4885LOXL2 1042/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | AOC1 3797/4885AOC3 3183/4885LOXL2 1859/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | AOC1 3797/4885AOC3 3183/4885LOXL2 1859/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | AOC1 3797/4885AOC3 3183/4885LOXL2 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.